8-K: Tevogen Bio Repurchases Preferred Stock and Faces Nasdaq Delisting Notice

Tevogen Bio Holdings Inc. repurchased all outstanding Series B Preferred Stock and received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement.

Summary

• Tevogen Bio Holdings Inc. repurchased all outstanding shares of its Series B Preferred Stock from SSVK Associates, LLC.
• The repurchase was completed by the company reassuming $3.6 million in liabilities previously assigned to SSVK.
• This transaction also terminated the Assignment and Assumption Agreement between the two parties.
• SSVK is a related party, with its managing member also serving on Tevogen's board of directors.
• Tevogen received a notice from Nasdaq for not meeting the minimum $1.00 per share bid price requirement.
• The company has 180 days, until December 11, 2024, to regain compliance.
• If compliance is not achieved, Tevogen may be eligible for an additional 180-day period by transferring to the Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The document contains both positive and negative elements. The repurchase of preferred stock is a positive step, but the delisting notice is a significant negative, resulting in an overall negative sentiment.

Positives

• The repurchase of preferred stock simplifies the company's capital structure by eliminating the Series B Preferred Stock.
• The termination of the Assignment and Assumption Agreement removes potential future obligations related to that agreement.

Negatives

• Tevogen received a delisting notice from Nasdaq due to its stock price falling below the minimum bid price of $1.00.
• The company faces the risk of being delisted from the Nasdaq Global Market if it cannot regain compliance by December 11, 2024.

Risks

• The company's stock price may continue to decline, making it difficult to regain compliance with Nasdaq's minimum bid price requirement.
• There is no guarantee that Tevogen will be able to regain compliance or maintain its listing on Nasdaq.
• The potential transfer to the Nasdaq Capital Market could negatively impact investor perception and liquidity.
• The company may need to consider a reverse stock split or other measures to increase its share price.

Future Outlook

The company intends to actively monitor the closing bid price of its common stock and evaluate options to regain compliance with Nasdaq listing rules, but there is no assurance that it will be successful.

Management Comments

• The company intends to actively monitor the closing bid price of the Common Stock and may, if appropriate, evaluate available options to regain compliance with the Bid Price Requirement.

Industry Context

The biotech industry is facing increased scrutiny and volatility, with many companies struggling to maintain their stock prices. This delisting notice highlights the challenges faced by smaller biotech firms in a competitive market.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges in maintaining Nasdaq listing compliance, particularly those with limited revenue and ongoing research and development costs.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced scrutiny and volatility in their stock prices, highlighting the risks associated with investing in early-stage biotech companies.
• The need to maintain a minimum bid price is a common hurdle for companies in this sector, and many have had to resort to reverse stock splits or other measures to avoid delisting.

Related Party Transactions

• The repurchase of preferred stock was a related party transaction with SSVK Associates, LLC, whose managing member is also a member of Tevogen's board of directors.

Stakeholder Impact

• Shareholders may be concerned about the potential delisting and the impact on the company's stock price.
• Employees may be affected by the uncertainty surrounding the company's future.
• Creditors may be concerned about the company's financial stability.

Next Steps

• Tevogen will need to monitor its stock price and take action to regain compliance with Nasdaq's minimum bid price requirement.
• The company may need to consider a reverse stock split or other measures to increase its share price.
• Tevogen may need to transfer to the Nasdaq Capital Market if it cannot regain compliance by the deadline.

Key Dates

Keywords

Tevogen Bio, Preferred Stock Repurchase, Nasdaq Delisting, Minimum Bid Price, SSVK Associates, Compliance, Series B Preferred Stock, Delisting Notice